Recent News

• 03.17.2026 - Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer
• 03.02.2026 - Myriad Commercially Launches Precise MRD with Select Community Oncologists
• 02.23.2026 - Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution

Recent Filings

• 03.16.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.16.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.16.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.16.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.16.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.16.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.16.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.16.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.09.2026 - 4 Statement of changes in beneficial ownership of securities
• 03.04.2026 - 424B3 Prospectus [Rule 424(b)(3)]